The FDA is requiring that Avodart and Proscar manufacturers disclose that there is an approximately 50% increased incidence of high grade prostate cancer with their usage. It also pointed out that they are not approved for prostate cancer prevention. These drugs block the conversion of testosterone to dihydro-testosterone, which is believed to be one the causes of BPH and low grade prostate cancer.
